Aldose reductase and the development of renal disease in diabetic dogs

Journal of Diabetes and its Complications

Volumn 13, Issue 1, 1999, Pages 10-16

  Kern, Timothy S ^a   Engerman, Ronald L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; GALACTOSE; HEMOGLOBIN A1C; POLYOL; SORBINIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOG; GALACTOSEMIA; GLUCOSE BLOOD LEVEL; GLUCOSURIA; KIDNEY DISEASE; KIDNEY HYPERTROPHY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS;

ALBUMINURIA; ALDEHYDE REDUCTASE; ANALYSIS OF VARIANCE; ANIMALS; BASEMENT MEMBRANE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOGS; ENZYME INHIBITORS; ERYTHROCYTES; GALACTOSE; GLOMERULAR MESANGIUM; GLYCOSURIA; IMIDAZOLES; IMIDAZOLIDINES; KIDNEY; KIDNEY CORTEX; KIDNEY GLOMERULUS; SUGAR ALCOHOLS; TIME FACTORS;

EID: 0032950386     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(98)00015-4     Document Type: Article

References (35)

1. Beyer-Mears A., Cruz E., Edelist T., Varagrannis E. Diminished proteinuria in diabetes by Sorbinil, an aldose reductase inhibitor. Pharmacology. 32:1986;52-60.
2. Goldfarb S., Simmons D.A., Kern E.F.O. Amelioration of glomerular hyperfiltration in acute experimental diabetes mellitus by dietary myo-inositol supplementation and aldose reductase inhibition. Trans Assoc Am Physicians. 99:1986;67-72.
3. McCaleb M.L., Sredy J., Millen J., Ackerman D.M., Dvornik D. Prevention of urinary albumin excretion in 6 month streptozotocin-diabetic rats with the aldose reductase inhibitor Tolrestat. J Diabet Complications. 2:1988;16-18.
4. Bank N., Mower P., Aynedjian H.S., Wilkes B.M., Silverman S. Sorbinil prevents glomerular hyperfusion in diabetic rats. Am J Physiol. 256:1989;F1000-F1006.
5. Tilton R.G., Chang K., Pugliese G., Eades D.M., Province M.A., Sherman W.R., Kilo C., Williamson J.R. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes. 37:1989;1258-1270.
6. Mauer S.M., Steffes M.W., Azar S., Brown D.M. Effects of Sorbinil on glomerular structure and function in long-term diabetic rats. Diabetes. 38:1989;839-846.
7. Osterby R., Gunderson H.J.G. Glomerular basement membrane thickening in streptozotocin diabetic rats despite treatment with an aldose reductase inhibitor. J Diabet Complications. 3:1989;149-153.
8. McCaleb M.L., McKean M.L., Hohman T.C., Laver N., Robison W.G. Jr. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats. Diabetologia. 34:1991;695-701.
9. Chang W.P., Dimitriadis E., Allen T., Dunlop M., Cooper M., Larkins R.G. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus. Diabetologia. 34:1991;225-231.
10. Pedersen M.M., Christiansen J.S., Mogensen C.E. Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition. Diabetes. 40:1991;527-531.
11. Passariello N., Sepe J., Marrazzo G., De Cicco A., Peluso A., Pisano M.C. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate. Diabetes Care. 16:1993;789-795.
12. Oates P.J. Diabetic nephropathy, renal hemodynamics, and aldose reductase inhibitors. Drug Dev Res. 32:1994;104-116.
13. Connelly S.M., Zhou X.P., Huang J.T., Whiteside C.I. Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat. Biochem Cell Biol. 74:1996;355-362.
14. Daniels B.S., Hostetter T.H. Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes. 38:1989;981-986.
15. Das A., Frank R.N., Zhang N.L. Sorbinil does not prevent galactose-induced glomerular capillary basement membrane thickening in the rat. Diabetologia. 33:1990;515-521.
16. Tilton R.G., Pugliese G., LaRose L.S., Faller A.M., Chang K., Province M.A., Williamson J.R. Discordant effects of the aldose reductase inhibitor Sorbinil on vascular structure and function in chronically diabetic and galactosemic rats. J Diabet Complications. 5:1991;230-237.
17. Kern T.S., Engerman R.L. Renal hemodynamics in experimentally galactosemic dogs and diabetic dogs. Metabolism. 40:1991;450-454.
18. Korner A., Celsi G., Eklof A.-C., Linne T., Persson B., Aperia A. Sorbinil does not prevent hyperfiltration, elevated ultrafiltration pressure and albuminuria in streptozotocin-diabetic rats. Diabetologia. 35:1992;414-418.
19. Reddi A.S., Jyothirmayi G.N. Aldose reductase inhibition by ponalrestat (Statil) does not prevent proteinuria in long-term diabetic rats. J Diabet Complications. 7:1993;233-240.
20. Soulis-Liparota T., Cooper M., Dunlop M., Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia. 38:1995;387-394.
21. Kern T.S., Engerman R.L. Kidney morphology in experimental hyperglycemia. Diabetes. 36:1987;244-249.
22. Engerman R.L., Kern T.S. Hyperglycemia and development of glomerular pathology. Diabetes compared with galactosemia Kidney Int. 36:1989;41-45.
23. Engerman R.L., Kern T.S., Larson M.E. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosemia in dogs. Diabetologia. 37:1994;141-144.
24. Engerman R.L., Kern T.S. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes. 42:1993;820-825.
25. Engerman R.L., Kern T.S., Garment M.B. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition. J Diabet Complications. 7:1993;241-245.
26. Malone J.I., Knox G., Benford S., Tedesco S. Red cell sorbitol. An indicator of diabetic control Diabetes. 29:1980;861-864.
27. Kern T.S., Engerman R.L. Retinal polyol and myo-inositol in galactosemic dogs given an aldose reductase inhibitor. Invest Ophthalmol Vis Sci. 32:1991;3175-3177.
28. Bilous R.W., Mauer S.M., Sutherland D.E.R., Steffes M.W. Mean glomerular volume and rate of development of diabetic nephropathy. Diabetes. 38:1989;1142-1147.
29. Steffes M.W., Brown D.M., Basgen J.M., Mauer S.M. Amelioration of mesangial volume and surface alterations following islet transplantation in diabetic rats. Diabetes. 29:1980;509-515.
30. Steffes M.W., Brown D.M., Basgen J.M., Matas A.J., Mauer S.M. Glomerular basement membrane thickness following islet transplantation in the diabetic rat. Lab Invest. 41:1979;116-118.
31. Kern T.S., Engerman R.L. Urinary protein excretion rates in experimentally diabetic dogs and experimentally galactosaemic dogs. Diabetologia. 31:1988;928-932.
32. Kern T.S., Engerman R.L. Arrest of glomerulopathy in diabetic dogs by improved glycemic control. Diabetologia. 33:1990;522-525.
33. Donnelly S.M., Zhou X.P., Huang J.T., Whiteside C.I. Prevention of early glomerulopathy with tolrestat in the streptozocin-induced diabetic rat. Biochem Cell Biol. 74:1996;355-362.
34. Craven P.A., DeRubertis F.R. Sorbinil suppresses glomerular prostaglandin production in the streptozotocin diabetic rat. Metabolism. 38:1989;649-654.
35. Pugliese G., Tilton R.G., Speedy A., Chang K., Province M.A., Kilo C., Williamson J.R. Vascular filtration function in galactose-fed versus diabetic rats. The role of polyol pathway activity Metabolism. 39:1990;690-697.